| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 09/20/2011 | CA2377977C Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes |
| 09/20/2011 | CA2356009C Vascular endothelial growth factor-x |
| 09/20/2011 | CA2115828C Calcium receptor active molecules |
| 09/15/2011 | WO2011113065A2 Pegylated polyplexes for polynucleotide delivery |
| 09/15/2011 | WO2011113048A2 Modulation of cytokine signaling |
| 09/15/2011 | WO2011113027A2 Npp1 fusion proteins |
| 09/15/2011 | WO2011112840A2 Water-soluble phytosterol derivatives for reducing cholesterol and preparation thereof |
| 09/15/2011 | WO2011112838A2 Composition and method for treatment of vascular hyperpermeability |
| 09/15/2011 | WO2011112732A2 Methods of treating vascular inflammatory disorders |
| 09/15/2011 | WO2011112679A1 Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same |
| 09/15/2011 | WO2011112116A1 Bath drug and method for using said drug in the treatment and prophylaxis of discirculatory encephalopathy |
| 09/15/2011 | WO2011111914A1 Vascular endothelial progenitor cells introduced with haptoglobin gene, and composition containing same for promoting angiogenesis |
| 09/15/2011 | WO2011111824A1 Method for proliferating cardiomyocytes using micro-rna |
| 09/15/2011 | WO2011111714A1 Novel ep4 agonist |
| 09/15/2011 | WO2011111698A1 MONOCLONAL ANTIBODY AGAINST NECROSIS MARKER ERp29 AND USE THEREOF |
| 09/15/2011 | WO2011111694A1 Monoclonal antibody against necrosis marker prdx4 and use thereof |
| 09/15/2011 | WO2011111581A1 Therapeutic agent and therapeutic device for alleviating ischemia-reperfusion injury |
| 09/15/2011 | WO2011111026A1 Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for administration shortly after amiodarone discontinuation |
| 09/15/2011 | WO2011110612A1 Inhibitors of protein kinases |
| 09/15/2011 | WO2011041989A3 Tricyclic and tetracyclic systems with activity on the central-nervous and vascular systems |
| 09/15/2011 | WO2010146407A9 Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them |
| 09/15/2011 | US20110224302 Difluorophenyldiacylhydrazide derivatives |
| 09/15/2011 | US20110224293 Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
| 09/15/2011 | US20110224275 Inhibitors of matrix metalloproteinases |
| 09/15/2011 | US20110224271 process for the preparation of olmesartan medoxomil |
| 09/15/2011 | US20110224268 Compositions and methods of using R(+) pramipexole |
| 09/15/2011 | US20110224267 Selective androgen receptor modulators |
| 09/15/2011 | US20110224262 Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
| 09/15/2011 | US20110224261 Crystalline form of 4-(5--4-methyl-4h-1,2,4-triazol-3-yl)pyridine |
| 09/15/2011 | US20110224260 Catechol-based derivatives for treating or preventing diabetics |
| 09/15/2011 | US20110224251 Therapeutic Pyrazolyl Thienopyridines |
| 09/15/2011 | US20110224250 Isoquinoline derivative, and pde inhibitor comprising same as active ingredient |
| 09/15/2011 | US20110224248 Azaquinolones that inhibit prolyl hydroxylase |
| 09/15/2011 | US20110224236 Treatment for pulmonary hypertension |
| 09/15/2011 | US20110224229 Novel Crystalline Form |
| 09/15/2011 | US20110224225 Inhibitors of protein kinases |
| 09/15/2011 | US20110224223 MTOR Modulators and Uses Thereof |
| 09/15/2011 | US20110224220 Substituted tricyclic derivatives |
| 09/15/2011 | US20110224213 Use of Glutaric Acid Derivatives or the Pharmaceutically Acceptable Salts Thereof as Anti-Arrhythmic Agents |
| 09/15/2011 | US20110224209 4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (dpp-1) |
| 09/15/2011 | US20110224199 Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues |
| 09/15/2011 | US20110224197 Pyrimidines and pyridines useful as inhibitors of protein kinases |
| 09/15/2011 | US20110224193 Inhibitors of diacylglycerol acyltransferase |
| 09/15/2011 | US20110224192 3-Arylamino Pyridine Derivatives |
| 09/15/2011 | US20110224189 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases |
| 09/15/2011 | US20110224188 DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES |
| 09/15/2011 | US20110224187 Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof |
| 09/15/2011 | US20110224185 Compounds and compositions as modulators of gpr119 activity |
| 09/15/2011 | US20110224176 Lyophilized Cake Formulations |
| 09/15/2011 | US20110224172 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods |
| 09/15/2011 | US20110224171 Inhibitors of fatty acid amide hydrolase |
| 09/15/2011 | US20110224166 COMPOSITION FOR ACTIVATING MITOCHONDRIA (As Amended) |
| 09/15/2011 | US20110224157 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS |
| 09/15/2011 | US20110224139 Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
| 09/15/2011 | US20110224135 Use of conkunitzin-s1 for the modulation of glucose-induced insulin secretion |
| 09/15/2011 | US20110223270 Uses of curculigo latifolia (c. latifolia) extracts |
| 09/15/2011 | US20110223254 Functionalized diphenolics and absorbable polymers therefrom |
| 09/15/2011 | US20110223249 Extended release compositions comprising mycophenolate sodium and processes thereof |
| 09/15/2011 | US20110223232 drug-release composition having a therapeutic carrier |
| 09/15/2011 | US20110223216 Nanoparticles and Porous Particles and Methods of Making the Same |
| 09/15/2011 | US20110223213 Highly pure ranolazine or a pharmaceutically acceptable salt thereof |
| 09/15/2011 | US20110223211 Pharmaceutical formulations containing irbesartan |
| 09/15/2011 | US20110223206 Micelle compositions and process for the preparation thereof |
| 09/15/2011 | US20110223203 Nanocluster compositions and methods |
| 09/15/2011 | US20110223184 Dkk2 protein and use thereof |
| 09/15/2011 | US20110223158 Association of levels of hdl-cholesterol apolipoprotein ciii with the risk of coronary heart disease and cardiovascular events |
| 09/15/2011 | US20110223144 Creation of a Biological Atrioventricular Bypass to Compensate for Atrioventricular Block |
| 09/15/2011 | US20110223141 Treatment of brain or spinal cord injury using placental stem cells |
| 09/15/2011 | US20110223138 Mesenchymal stem cells that express increased amounts of anti-apoptotic proteins |
| 09/15/2011 | US20110223127 SDF-1 Binding Nucleic Acids And The Use Thereof |
| 09/15/2011 | US20110220265 Preparation for External Use |
| 09/15/2011 | CA2792743A1 Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for administration shortly after amiodarone discontinuation |
| 09/15/2011 | CA2792520A1 Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same |
| 09/15/2011 | CA2792411A1 Method for proliferating cardiomyocytes using micro-rna |
| 09/15/2011 | CA2792403A1 Novel ep4 agonist |
| 09/15/2011 | CA2789189A1 Inhibitors of protein kinases |
| 09/14/2011 | EP2365085A1 Growth hormone fusion protein |
| 09/14/2011 | EP2365004A2 Membrane associated tumor endothelium markers |
| 09/14/2011 | EP2364982A1 Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof |
| 09/14/2011 | EP2364731A2 Methods of administering anti-TNFalpha antibodies |
| 09/14/2011 | EP2364711A1 Use of extracts from rabbit skin inflamed by vaccinia virus for the manufacture of a medicament for the treatment of acute cerebrovascular disease |
| 09/14/2011 | EP2364710A1 Therapeutic use of D-allose |
| 09/14/2011 | EP2364708A2 Pharmaceutical composition comprising a C1C-2 channel opener |
| 09/14/2011 | EP2364703A1 Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for administration shortly after amiodarone discontinuation |
| 09/14/2011 | EP2364701A1 Omega-3 fatty acid formulations |
| 09/14/2011 | EP2364699A1 Joint use of sulfonamide based compound with angiogenesis inhibitor |
| 09/14/2011 | EP2364316A1 6, 7 -dihydro- 5h- pyrrolo [3, 4-d¨pyrimidin-4-yl]-quinolin-3 -ylamine compounds useful as FAAH modulators and uses thereof |
| 09/14/2011 | EP2364313A1 Aza-benzimidazolone chymase inhibitors |
| 09/14/2011 | EP2364311A1 Tropane urea derivatives, preparation thereof and therapeutic application thereof as modulators of the activity of 11betahsd1 |
| 09/14/2011 | EP2364292A2 Amide inhibitors of renin |
| 09/14/2011 | EP2364151A1 Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury |
| 09/14/2011 | EP1926727B1 4-chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof |
| 09/14/2011 | EP1713480B1 The use of quaternary pyridinium salts as vasoprotective agents |
| 09/14/2011 | EP1534277B1 Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
| 09/14/2011 | EP1358215B1 Glycosaminoglycans derived from k5 polysaccharide having high antithrombin activity and process for their preparation |
| 09/14/2011 | EP1257264B1 Estrogen receptor modulators |
| 09/14/2011 | CN1954825B Supermicro Tongxinluo Chinese herbal composite and its new usage |
| 09/14/2011 | CN1872879B Anagonism active polypeptide of CXCR4 acceptor from inflammation protein of virus macrophage |
| 09/14/2011 | CN1868507B Medicine composition, preparation method and application thereof |
| 09/14/2011 | CN1823765B Indapamide percutaneous controlled release plaster and its preparation method |